Which ETFs hold NTRA? Natera Inc is held by 2 funds tracked by ETFpeek.

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
| Date | Person | Action | Plan | Shares | Value | Score |
|---|---|---|---|---|---|---|
| 1 Oct 2026 | Solomon Moshkevich President of Clinical Diagnostics | SELL | Unknown | 1,846 | $766K | 50 |
| 1 Oct 2026 | Steven Leonard Chapman CEO & Director | SELL | Unknown | 1,273 | $526K | 50 |
| 23 Sep 2026 | Jonathan Sheena Co-Founder & Director | SELL | Unknown | 16,944 8 tranches | $6.6M | 60 |
| 10 Aug 2026 | John Fesko President & Chief Business Officer | SELL | Unknown | 6,517 | $2.1M | 90 |
| 10 Aug 2026 | Jonathan Sheena Co-Founder & Director | SELL | Unknown | 6,000 | $2.0M | 90 |
| 7 Aug 2026 | Jonathan Sheena Co-Founder & Director | SELL | Unknown | 5,111 | $1.6M | 90 |
| 7 Aug 2026 | Matthew Rabinowitz Co-Founder & Executive Chairman | SELL | Unknown | 2,000 | $642K | 80 |
| 28 Jul 2026 | Steven Leonard Chapman CEO & Director | SELL | Unknown | 3,580 | $910K | 80 |
| 27 Jul 2026 | Steven Leonard Chapman CEO & Director | SELL | Unknown | 2,190 | $570K | 80 |
| Date | Person | Action | Plan | Shares | Value | Score |
|---|---|---|---|---|---|---|
| 1 Oct 2026 | Solomon Moshkevich President of Clinical Diagnostics | SELL | Unknown | 3,000 3 tranches | $1.2M | 50 |
| 1 Oct 2026 | Steven Leonard Chapman CEO & Director | SELL | Unknown | 1,273 | $526K | 50 |
| 23 Sep 2026 | Jonathan Sheena Co-Founder & Director | SELL | Unknown | 18,064 12 tranches | $7.0M | 60 |
| 10 Aug 2026 | John Fesko President & Chief Business Officer | SELL | Unknown | 6,517 | $2.1M | 90 |
| 10 Aug 2026 | Jonathan Sheena Co-Founder & Director | SELL | Unknown | 6,000 | $2.0M | 90 |
| 7 Aug 2026 | Jonathan Sheena Co-Founder & Director | SELL | Unknown | 8,650 8 tranches | $2.7M | 90 |
| 7 Aug 2026 | Matthew Rabinowitz Co-Founder & Executive Chairman | SELL | Unknown | 2,000 | $642K | 80 |
| 6 Aug 2026 | John Fesko President & Chief Business Officer | BUY | Vested (RSU) | 20,000 | — | 0 |
| 4 Aug 2026 | Michael Burkes Brophy Chief Financial Officer | SELL | Unknown | 478 | $131K | 30 |
| 3 Aug 2026 | John Fesko President & Chief Business Officer | SELL | Unknown | 295 | $79K | 30 |
| 3 Aug 2026 | Solomon Moshkevich President of Clinical Diagnostics | SELL | Unknown | 3,410 7 tranches | $906K | 30 |
| 3 Aug 2026 | Daniel Rabinowitz Secretary & Chief Legal Officer | SELL | Unknown | 334 | $90K | 30 |
| 3 Aug 2026 | Steven Leonard Chapman CEO & Director | SELL | Unknown | 3,076 7 tranches | $819K | 30 |
| 3 Aug 2026 | Michael Burkes Brophy Chief Financial Officer | SELL | Unknown | 317 | $85K | 30 |
| 3 Aug 2026 | Jonathan Sheena Co-Founder & Director | SELL | Unknown | 109 | $29K | 30 |
| 3 Aug 2026 | Matthew Rabinowitz Co-Founder & Executive Chairman | SELL | Unknown | 731 | $196K | 30 |
| 29 Jul 2026 | Michael Burkes Brophy Chief Financial Officer | SELL | Unknown | 1,863 | $465K | 30 |
| 28 Jul 2026 | Steven Leonard Chapman CEO & Director | SELL | Unknown | 3,580 | $910K | 80 |
| 28 Jul 2026 | John Fesko President & Chief Business Officer | SELL | Unknown | 931 | $237K | 30 |
| 28 Jul 2026 | Solomon Moshkevich President of Clinical Diagnostics | SELL | Unknown | 1,204 | $306K | 30 |
| 28 Jul 2026 | Daniel Rabinowitz Secretary & Chief Legal Officer | SELL | Unknown | 1,003 | $255K | 30 |
| 28 Jul 2026 | Michael Burkes Brophy Chief Financial Officer | SELL | Unknown | 2,419 3 tranches | $614K | 30 |
| 28 Jul 2026 | Jonathan Sheena Co-Founder & Director | SELL | Unknown | 191 | $49K | 30 |
| 27 Jul 2026 | Steven Leonard Chapman CEO & Director | SELL | Unknown | 2,190 | $570K | 80 |
| 27 Jul 2026 | John Fesko President & Chief Business Officer | SELL | Unknown | 782 | $204K | 30 |
| 27 Jul 2026 | Solomon Moshkevich President of Clinical Diagnostics | SELL | Unknown | 1,010 | $263K | 30 |
| 27 Jul 2026 | Daniel Rabinowitz Secretary & Chief Legal Officer | SELL | Unknown | 884 | $230K | 30 |
| 27 Jul 2026 | Michael Burkes Brophy Chief Financial Officer | SELL | Unknown | 782 | $204K | 30 |
| 27 Jul 2026 | Jonathan Sheena Co-Founder & Director | SELL | Unknown | 288 | $75K | 30 |
| 27 Jul 2026 | Matthew Rabinowitz Co-Founder & Executive Chairman | SELL | Unknown | 1,718 | $448K | 30 |
| 15 Jul 2026 | Rowan E Chapman Director / Other | SELL | Unknown | 135 | $37K | 30 |
| 15 Jul 2026 | Jonathan Sheena Co-Founder & Director | SELL | Unknown | 1,500 8 tranches | $411K | 30 |
| 13 Jul 2026 | Jonathan Sheena Co-Founder & Director | SELL | Unknown | 2,150 4 tranches | $572K | 30 |
| Date | Fund | Direction | Shares Changed | % Δ ETF | % Δ Position |
|---|---|---|---|---|---|
| 9 Oct 2026 | ARKK | SELLReduced | -19,446 | -0.13% | 9.48% |
| 15 Sep 2026 | ARKK | SELLReduced | -7,803 | +0.00% | 3.69% |
| 18 Aug 2026 | ARKK | SELLReduced | -20,309 | -0.09% | 8.65% |
| 5 Aug 2026 | ARKK | SELLReduced | -3,207 | -0.05% | 1.32% |
| 4 Aug 2026 | ARKK | SELLReduced | -18,060 | -0.11% | 7.02% |
| 31 Jul 2026 | ARKK | SELLReduced | -4,485 | +0.05% | 1.70% |
| 29 Jul 2026 | ARKK | SELLReduced | -6,746 | -0.10% | 2.53% |
| 21 Jul 2026 | ARKK | SELLReduced | -11,228 | -0.09% | 3.99% |
| 17 Jul 2026 | ARKK | SELLReduced | -19,373 | -0.07% | 6.40% |
| 10 Jul 2026 | ARKK | SELLReduced | -21,580 | -0.07% | 6.28% |
| 10 Jul 2026 | ARKG | SELLReduced | -4,889 | -0.07% | 2.00% |
| 9 Jul 2026 | ARKK | SELLReduced | -14,051 | -0.07% | 4.04% |
| 9 Jul 2026 | ARKG | SELLReduced | -2,893 | -0.09% | 1.17% |
| 8 Jul 2026 | ARKK | SELLReduced | -12,554 | -0.03% | 3.48% |
| 8 Jul 2026 | ARKG | SELLReduced | -8,439 | -0.07% | 3.28% |
| 16 Jun 2026 | ARKK | SELLReduced | -5,845 | -0.10% | 1.42% |
| 12 Jun 2026 | ARKK | SELLReduced | -25,532 | -0.07% | 4.98% |
| No trade history for SmartShares funds — their underlying ETFs are passive index trackers, so day-to-day rebalancing is minimal. | |||||